Gewinn- und Verlustrechnung von Vertex Pharmaceuticals

zacks.com2026-10-05 10:01:07

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

fool.com2026-10-04 10:14:57

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Amgen offers a diversified portfolio of established therapies across oncology and inflammation supported by robust cash flow. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market and is expanding into high-growth gene therapies.

zacks.com2026-10-01 19:00:59

Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.

fool.com2026-10-01 14:57:35

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Axsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders. Vertex Pharmaceuticals remains a highly profitable giant with absolute dominance in cystic fibrosis and expanding reach in gene therapy.

etftrends.com2026-09-30 07:06:16

The Top HealthTech Questions Landing on Our Desks

Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).

fool.com2026-09-29 05:10:00

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.

Vertex Pharmaceuticals is the leader in the cystic fibrosis market and has the intellectual property to maintain this dominance. The company has expanded into additional treatment areas and is awaiting a regulatory decision for another potential new product in the coming weeks.

fool.com2026-09-26 16:01:01

2 Healthcare Stocks That Just Delivered Great News for Investors

Vertex Pharmaceuticals and Amgen recently posted strong clinical trial results for promising candidates. Both companies have robust businesses and strong medium-term prospects.

zacks.com2026-09-24 18:51:05

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know

Vertex Pharmaceuticals (VRTX) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day.

fool.com2026-09-24 08:42:37

CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

CRISPR Therapeutics is transitioning into a commercial-stage company with its pioneering gene-editing treatment, CASGEVY. Vertex Pharmaceuticals maintains a dominant, highly profitable position in the global cystic fibrosis market.

zacks.com2026-09-23 13:11:07

Vertex Posts Positive Phase II Data on Kidney Disease Drug

VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.

Erläuterung zur Gewinn- und Verlustrechnung

Erläuterung zur Ertragskraft

Gewinn- und Verlustrechnung von Vertex Pharmaceuticals Incorporated

Erläuterung zur Gewinn- und Verlustrechnung

Erläuterung zur Ertragskraft